1435108个取卵周期中重度卵巢过度刺激综合征与严重腹腔内出血的发生率及危险因素
该回顾性队列研究基于日本ART登记数据2007至2015年1,435,108个取卵周期,分析中重度OHSS与严重腹腔内出血的发生率及危险因素。中重度OHSS和严重腹腔内出血发生率分别为0.79%和0.08%,且逐年下降。GnRH激动剂方案和新鲜胚胎移植后临床妊娠是两类并发症的最高危险因素。
要点
- 中重度OHSS发生率0.79%,严重腹腔内出血发生率0.08%,2007至2015年分别下降0.57倍和0.29倍。
- GnRH激动剂方案是OHSS(OR 1.83)和腹腔内出血(OR 1.24)的最高危险因素。
- 新鲜胚胎移植后临床妊娠增加OHSS(OR 1.19)和腹腔内出血(OR 2.34)风险。
核心结论
- 影响OHSS和腹腔内出血的最高危险因素是GnRH激动剂方案及新鲜胚胎移植后临床妊娠。
- 随着GnRH激动剂使用和新鲜胚胎移植减少,OHSS和腹腔内出血发生率逐年下降。
研究设计与样本
- 回顾性队列研究,基于日本ART登记数据2007至2015年共1,435,108个取卵周期。
- 纳入中重度OHSS 11,378个周期,严重腹腔内出血1,182个周期(其中27个周期两者兼有),无这两类并发症1,422,575个周期。
主要发现
- 中重度OHSS发生率为0.79%,严重腹腔内出血发生率为0.08%。
- 2007至2015年,中重度OHSS发生率下降0.57倍,严重腹腔内出血发生率下降0.29倍。
- OHSS周期和腹腔内出血周期中,女性更年轻(OR分别为0.91和0.95),获卵数更多(OR分别为1.09和1.01)。
- GnRH激动剂方案是OHSS(OR 1.83)和腹腔内出血(OR 1.24)的最高危险因素,其次为GnRH拮抗剂方案(参照),促性腺激素联合或不联合口服药(OR分别为0.45和0.56),自然周期或口服药(OR分别为0.02和0.19)。
- 新鲜胚胎移植中,临床妊娠与OHSS风险增加(OR 1.19)和腹腔内出血风险增加(OR 2.34)相关。
临床怎么用
- 对使用GnRH激动剂方案及新鲜胚胎移植后临床妊娠的周期,应加强OHSS和腹腔内出血的监测与预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: What are the risk factors affecting the incidences of moderate-to-severe ovarian hyperstimulation syndrome (OHSS) and severe hemoperitoneum in assisted reproductive technology (ART) treatment cycles? DESIGN: A retrospective cohort study was conducted on 1,435,108 oocyte retrieval cycles among Japanese ART registry data between 2007 and 2015. The study included 11,378 cycles with moderate-to-severe OHSS, 1182 cycles with severe hemoperitoneum, including 27 cycles with both conditions, and 1,422,575 cycles without moderate-to-severe OHSS and severe hemoperitoneum. RESULTS: The incidences of moderate-to-severe OHSS and severe hemoperitoneum were 0.79% and 0.08%, respectively, and decreased by 0.57-fold and 0.29-fold from 2007 to 2015, respectively. In cycles with OHSS and cycles with hemoperitoneum women were younger (odds ratios [OR] 0.91 and 0.95, respectively) and had more retrieved oocytes (OR 1.09 and 1.01, respectively) compared with cycles without both complications. The use of a gonadotrophin-releasing hormone (GnRH) agonist protocol for ovarian stimulation was the highest risk factor in cycles with OHSS and hemoperitoneum (OR 1.83 and 1.24, respectively), followed by GnRH antagonist protocol (reference), gonadotrophin with or without oral medicine (OR 0.45 and 0.56, respectively) and natural or oral medicine (OR 0.02 and 0.19, respectively). In fresh embryo transfer, clinical pregnancy was associated with an increased risk of OHSS and hemoperitoneum (OR 1.19 and 2.34, respectively). CONCLUSIONS: The highest risk factors affecting OHSS and hemoperitoneum were the use of a GnRH agonist protocol and clinical pregnancy following fresh embryo transfer. The incidences of OHSS and hemoperitoneum have decreased yearly with a reduction of GnRH agonist use and fresh embryo transfer.
引用
- Kuroda K, Nagai S, Ikemoto Y, et al. Incidences and risk factors of moderate-to-severe ovarian hyperstimulation syndrome and severe hemoperitoneum in 1,435,108 oocyte retrievals. Reprod Biomed Online. 2020. PMID: 33051135. doi:10.1016/j.rbmo.2020.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。